NeuroSense Therapeutics Ltd (NRSN) Actualités

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

NeuroSense Recaps Positive 2023 Achievements Including Statistically Significant Slowing of Disease Progression in Phase 2b ALS Trial of PrimeC and Highlights Anticipated 2024 Catalysts

NeuroSense Recaps Positive 2023 Achievements Including Statistically Significant Slowing of Disease...

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

NeuroSense Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirement

NeuroSense Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirement PR...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

NeuroSense Reports New Data: Statistically Significant Clinical Efficacy in Phase 2b ALS Trial

NeuroSense Reports New Data: Statistically Significant Clinical Efficacy in Phase 2b ALS Trial PR...

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

NeuroSense's Phase 2b ALS Trial Achieves Primary Safety and Tolerability & Secondary Clinical Efficacy Endpoints

NeuroSense's Phase 2b ALS Trial Achieves Primary Safety and Tolerability & Secondary Clinical Efficacy...

Form EFFECT - Notice of Effectiveness